Please select the option that best describes you:
Topics:
Gynecologic Oncology • Endometrial Cancer • Medical Oncology • Journal Club ft. NEJM publications
What are real world exclusion criteria for the use of lenvatinib + pembrolizumab for advanced endometrial cancer?
Are there specific clinical or social scenarios that would preclude the use of this treatment?
Answer from: at Community Practice
Poorly controlled Hypertension
Active flare of autoimmune disease
On immunosuppressant therapies
Sign in or Register to read more
Answer from: at Academic Institution
Patients with active auto-immune disease or uncontrolled hypertension should give one pause.